Chronic kidney disease (CKD) is highly prevalent, with increasing numbers of patients affected by
the disease world-wide (1). Anemia is a common complica- tion that contributes to the burden of
disease associated with CK D, and it impacts negatively on cardiovascular disease, exercise capacity,
and quality of life, resulting in significant mortality and morbidity in patients with CKD (25). Anemia is
currently defined by the World Health Organization (WHO) as a hemoglobin (Hb) level o13 g/dL in men
and o12 g/dL in women (6).
Purpose: Impaired oxidative-antioxidative balance plays an important role in the pathogenesis of many
diseases like cancer. Ischemia modified albumin (IMA) is altered albumin by free radicals generated
from ischemic tissues. The aim of this study was to evaluate the levels of the IMA in newly diagnosed
patients with invasive ductal carcinoma and fibroadenoma before the surgery or medical treatment.
Methods: IMA levels were measured in 30 patients which were diagnosed as invasive ductal
carcinoma(Group 1), 30 patients as fibroadenoma(Group 2) and in 28 healthy controls(Group 3). An
albumin-cobalt binding test was used to define serum IMA in absorbance units (ABSU).
Results: There were statistically significant differences between three groups. IMA levels were
significantly higher in the invasive ductal carcinoma group (0.434±0.056 ABSU) compared to
fibroadenoma group (0.344±0.135 ABSU) and control group (0.196±0.050 ABSU) (p<0.05), also
fibroadenoma group values were significantly higher than the control group (p<0.05).
Conclusion: These findings indicate that serum IMA measurements can be demonstrative of the
severity of oxidative stress among patients with breast pathologies. Highest IMA levels in invasive ductal
carcinoma group than fibroadenoma and control groups may reflect disease severity in newly diagnosed
patients and in the future it may be a new marker in breast cancer.